LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global ocular inflammation treatment market to grow at a CAGR of more than 6% during the forecast period, according to their latest market research report. The growth momentum of the market is expected to accelerate in the year-over-year growth.
Technology advancement in drug delivery is one of the major trends being witnessed in the global ocular inflammation treatment market 2019-2023. The lack of advanced drug delivery methods is one of the major challenges faced by the ocular inflammation treatment market. The delivery of the drug into regions such as the middle layer of the eye is a highly complicated and painful method. Hence, the increasing need for technology advancement and novel drug delivery systems has led to the advent of small hair-strand size devices that can be implanted in the middle layer of the eye. Thus, such advances in novel drug delivery and technology advancement are attracting more patients due to the huge number of benefits associated with treatment and are expected to drive the market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
According to Technavio analysts, one of the key factors contributing to the growth of the global ocular inflammation treatment market is the strong drug pipeline:
Global ocular inflammation treatment market: Strong drug pipeline
Despite various therapies being approved for the ocular inflammation treatment, the market still has a huge unmet need which indicates towards the requirement of a strong drug pipeline. Hence, various pharmaceutical and biotechnology companies are conducting research on the development of impactful drugs. Thus, the strong drug pipeline for ocular inflammation treatment along with expected new approvals is expected to contribute to the market growth during the forecast period.
According to a senior analyst at Technavio for research on pharmaceuticals, “Sirolimus is a therapy under development by Santen pharmaceutical which is in phase III of clinical trials and has shown high efficacy and safety for treating ocular inflammation diseases. Similarly, ADX-102 is another drug in phase III of clinical trials that is expected to be launched in the market in 2019 and is expected to contribute to the market growth.”
Global ocular inflammation treatment market: Segmentation analysis
The global ocular inflammation treatment market research report provides market segmentation by product (corticosteroids, immunosuppressants, anti-infectives, and other drug classes) and by region (the Americas, EMEA, and APAC). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
The Americas held the largest share of the market in 2018, accounting for close to 44% share. It was followed by EMEA and APAC respectively. The dominance of the Americas can be attributed to the strong drug pipeline and growing awareness of eye care.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Market Landscape
- Market ecosystem
- Market characteristics
- Market segmentation analysis
Market Sizing
- Market definition
- Market size and forecast
Five Forces Analysis
Market Segmentation
Geographical Segmentation
- Regional comparison
- Key leading countries
Market Drivers
Market Challenges
Market Trends
Vendor Landscape
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
